PMC:7544934 / 5616-5953 JSONTXT

{"project":"LitCovid_Glycan-Motif-Structure","denotations":[{"id":"T15","span":{"begin":224,"end":227},"obj":"https://glytoucan.org/Structures/Glycans/G00057MO"},{"id":"T16","span":{"begin":224,"end":227},"obj":"https://glytoucan.org/Structures/Glycans/G31736BK"}],"text":"As a reliable COVID-19 vaccine is unlikely to available before the maximal infection of COVID-19 has occurred, it is essential to establish therapeutics for the COVID-19 patients, based on our data, we proposed FDA-approved LDN can be used in combination or as an adjuvants therapy to treat mild to moderate symptomatic COVID-19 patients"}

{"project":"LitCovid-PubTator","denotations":[{"id":"157","span":{"begin":170,"end":178},"obj":"Species"},{"id":"161","span":{"begin":14,"end":22},"obj":"Disease"},{"id":"162","span":{"begin":75,"end":84},"obj":"Disease"},{"id":"163","span":{"begin":88,"end":96},"obj":"Disease"},{"id":"164","span":{"begin":161,"end":169},"obj":"Disease"},{"id":"165","span":{"begin":320,"end":328},"obj":"Disease"}],"attributes":[{"id":"A157","pred":"tao:has_database_id","subj":"157","obj":"Tax:9606"},{"id":"A161","pred":"tao:has_database_id","subj":"161","obj":"MESH:C000657245"},{"id":"A162","pred":"tao:has_database_id","subj":"162","obj":"MESH:D007239"},{"id":"A163","pred":"tao:has_database_id","subj":"163","obj":"MESH:C000657245"},{"id":"A164","pred":"tao:has_database_id","subj":"164","obj":"MESH:C000657245"},{"id":"A165","pred":"tao:has_database_id","subj":"165","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"As a reliable COVID-19 vaccine is unlikely to available before the maximal infection of COVID-19 has occurred, it is essential to establish therapeutics for the COVID-19 patients, based on our data, we proposed FDA-approved LDN can be used in combination or as an adjuvants therapy to treat mild to moderate symptomatic COVID-19 patients"}

{"project":"LitCovid-sentences","denotations":[{"id":"T42","span":{"begin":0,"end":337},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"As a reliable COVID-19 vaccine is unlikely to available before the maximal infection of COVID-19 has occurred, it is essential to establish therapeutics for the COVID-19 patients, based on our data, we proposed FDA-approved LDN can be used in combination or as an adjuvants therapy to treat mild to moderate symptomatic COVID-19 patients"}